Amgen Inc (AMGN) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Amgen Inc. has initiated a Phase 3 clinical trial titled A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity. The study aims to assess the effectiveness and safety of maridebart cafraglutide in adults suffering from obstructive sleep apnea (OSA) who are also overweight or obese and are undergoing positive airway pressure (PAP) therapy.
The intervention being tested is maridebart cafraglutide, administered subcutaneously. This drug is intended to improve the condition of patients with OSA who are concurrently dealing with obesity, potentially enhancing their quality of life and treatment outcomes.
The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. Both participants and investigators are masked to ensure unbiased results, with the primary purpose being treatment evaluation.
The study is set to begin recruiting participants on November 5, 2025, with the last update submitted on December 4, 2025. These dates are crucial as they mark the progression of the study and its readiness to commence.
This update could positively influence Amgen’s stock performance by showcasing its commitment to addressing prevalent health issues like OSA and obesity. The potential success of maridebart cafraglutide could enhance investor sentiment, especially in a competitive pharmaceutical landscape where innovation is key.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.